<DOC>
	<DOCNO>NCT01941849</DOCNO>
	<brief_summary>The phase I trial aim determine recommend phase II dose ( RP2D ) vandetanib combination standard radiation therapy , 131I-mIBG , patient advance phaeochromocytoma ( phaeo ) paraganglioma ( PG ) assess safety tolerability combination treatment .</brief_summary>
	<brief_title>Phase I Trial Vandetanib Combined With 131I-mIBG Treat Patients With Advanced Phaeochromocytoma Paraganglioma</brief_title>
	<detailed_description>VIBRaNT register phase I trial patient locally advance metastatic phaeochromocytoma paraganglioma , amenable surgical resection . Patients receive vandetanib ( inhibitor VEGF , EGFR RET tyrosine kinase ) combination standard radiation therapy Iodine-131 label Meta-iodobenzylguanidine ( 131I-mIBG ) . Vandetanib 131I-mIBG give 12-weekly cycle : 131I-miBG give day 1 cycle vandetanib start day 1 cycle continue take every day . The phase I trial aim determine recommend phase II dose vandetanib ( either 100 , 200 300 mg daily ) - dose vandetanib patient receive depend dose investigation time patient registration . The vandetanib dose determine Modified Continual Reassessment Method ( mCRM ) - toxicity model describe probability toxicity occur dose level , base clinical judgement available toxicity data .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>1 . Histopathological/cytological diagnosis advance phaeo/PG define patient local metastatic disease amenable surgical resection , R1 resection post original surgical debulking 2 . Positive 123ImIBG diagnostic scan 3 . Stable blood pressure ( &lt; 140/90mmHg ) , appropriate , antihypertensive therapy 4 . No previous systemic chemotherapy within 3 month prior registration 5 . No previous mIBG therapy within 12 month prior registration ( previous cumulative activity must exceed 15 GBq ) 6 . Measurable disease ( RECIST v1.1 ) 7. WHO performance status 0 1 8 . Age ≥ 18 9 . Estimated life expectancy &gt; 3 month . 10 . Adequate bone marrow function : Haemoglobin ≥ 100 g/L , White Blood Cell ≥ 3.0 x 10^9/L , Absolute neutrophil ≥ 1.5 x 10^9/L , Platelet ≥ 100 x 10^9/L 11 . Adequate liver function : Total bilirubin ≤1.5 x Upper Limit Normal ( ULN ) ; ALT/AST ALP≤ 2.5 x ULN ≤ 5 x ULN relate liver metastasis 12 . Adequate renal function : Serum urea creatinine &lt; 1.5x ULN AND Calculated creatinine clearance ( GFR ) ≥50 mL/min . If calculate GFR 50 , isotope clearance test require confirm GFR ≥50 mL/min 13 . Electrolytes : Potassium ≥ 4.0 mmol/L ≤ 5.5 mmol/L , Magnesium ≥ Lower Limit Normal ≤ 1.23 mmol/L , Corrected calcium within institution normal range 14 . Negative pregnancy test woman childbearing potential AND use adequate barrier contraception , must continue 12 month completion treatment ( male patient must also agree use barrier contraception trial 12 month completion treatment ) 15 . Able swallow oral medication 16 . Capable give write informed consent 1 . Patients undergoing current treatment curative intent 2 . Previous current malignancy histological type within last 5 year ( exception list trial protocol ) 3 . Any prior exposure VEGF , EGFR RET inhibitor history hypersensitivity vandetanib excipient agent 4 . Evidence severe uncontrolled systemic disease laboratory find view investigator make undesirable patient participate trial 5 . Evidence active uncontrolled infection ( patient antibiotic eligible ) 6 . Chronic gastrointestinal disease ( e.g . Inflammatory Bowel Disease ) significant bowel resection would preclude adequate absorption 7 . Cardiovascular exclusion criterion ( complete list provide trial protocol ) : Significant cardiac event ( myocardial infarction ) , New York Heart Association Class II , within 12 week registration , presence cardiac disease opinion investigator increase risk ventricular arrhythmia Prior current cardiomyopathy Baseline LVEF &lt; 40 % measure ECHO/MUGA Atrial fibrillation heart rate &gt; 100 bpm Unstable ischaemic heart disease ( myocardial infarction within 6 month prior start treatment , angina require use nitrate weekly ) History arrhythmia symptomatic require treatment QTcB prolongation &gt; 480 m baseline QT prolongation medication require discontinuation medication 8 . Any psychiatric disorder likely impact inform consent ability manage isolation 9 . Major surgery within 28 day prior registration 10 . Brain metastasis spinal cord compression , unless treat least four week first dose stable without steroid treatment 10 day 11 . Any concomitant medication may affect QTc , induce inhibit CYP3A4 function ( exception somatostatin somatostatin analogue ) and/or prohibit medication 12 . Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phaeochromocytoma</keyword>
	<keyword>Paraganglioma</keyword>
	<keyword>Neuroendocrine Tumour</keyword>
	<keyword>Vandetanib</keyword>
	<keyword>131I-mIBG</keyword>
	<keyword>Radionucleotide Therapy</keyword>
	<keyword>Vascular Endothelial Growth Factor ( VEGF )</keyword>
	<keyword>Epidermal Growth Factor Receptor ( EGFR )</keyword>
	<keyword>RET</keyword>
	<keyword>Tyrosine Kinase</keyword>
</DOC>